Somewhat Negative Media Coverage Somewhat Unlikely to Impact Leap Therapeutics (LPTX) Share Price

Media coverage about Leap Therapeutics (NASDAQ:LPTX) has trended somewhat negative this week, according to Accern Sentiment. The research group ranks the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Leap Therapeutics earned a news impact score of -0.01 on Accern’s scale. Accern also assigned news stories about the company an impact score of 46.1508118876402 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Shares of LPTX stock opened at $8.90 on Monday. The stock has a market capitalization of $129.06, a PE ratio of -2.69 and a beta of -0.42. Leap Therapeutics has a 52-week low of $4.90 and a 52-week high of $10.01.

How to Become a New Pot Stock Millionaire

Leap Therapeutics (NASDAQ:LPTX) last released its quarterly earnings results on Friday, February 23rd. The company reported ($0.65) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.77) by $0.12. analysts predict that Leap Therapeutics will post -2.52 earnings per share for the current year.

A number of equities research analysts have recently issued reports on LPTX shares. Zacks Investment Research raised shares of Leap Therapeutics from a “hold” rating to a “buy” rating and set a $7.00 target price on the stock in a report on Tuesday, January 23rd. ValuEngine raised shares of Leap Therapeutics from a “strong sell” rating to a “sell” rating in a report on Thursday, March 22nd.

WARNING: “Somewhat Negative Media Coverage Somewhat Unlikely to Impact Leap Therapeutics (LPTX) Share Price” was published by Ticker Report and is the property of of Ticker Report. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international copyright and trademark law. The legal version of this report can be viewed at https://www.tickerreport.com/banking-finance/3343421/somewhat-negative-media-coverage-somewhat-unlikely-to-impact-leap-therapeutics-lptx-share-price.html.

Leap Therapeutics Company Profile

Leap Therapeutics, Inc, formerly HealthCare Pharmaceuticals, Inc, is a clinical-stage biopharmaceutical company. The Company engages in acquiring and developing therapeutics in cancer biology. Its lead product candidates for use in clinical trials include TRX518 and DKN-01. DKN-01 is a monoclonal antibody targeting Dickkopf-related protein 1 (DKK1).

Insider Buying and Selling by Quarter for Leap Therapeutics (NASDAQ:LPTX)

Receive News & Ratings for Leap Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

XYLO 24-Hour Volume Tops $0.00
XYLO 24-Hour Volume Tops $0.00
Financial Survey: Boot Barn  & Foot Locker
Financial Survey: Boot Barn & Foot Locker
Yelp  versus Weight Watchers  Head-To-Head Contrast
Yelp versus Weight Watchers Head-To-Head Contrast
Reviewing Zynex  & Its Competitors
Reviewing Zynex & Its Competitors
Animecoin Price Reaches $0.0111 on Exchanges
Animecoin Price Reaches $0.0111 on Exchanges
Elcoin   Trading 13% Lower  Over Last 7 Days
Elcoin Trading 13% Lower Over Last 7 Days


Leave a Reply

© 2006-2018 Ticker Report. Google+.